The Supreme Court unanimously held that induced patent infringement claims require specific, affirmative acts of encouragement, protecting the generic-drug skinny-label pathway.
The Supreme Court unanimously reversed the Federal Circuit on June 4, 2026, holding that a plaintiff asserting induced patent infringement under 35 U.S.C. § 271(b) must allege that the defendant took active, affirmative steps clearly directed at encouraging the infringing use [1]. Neutral or ambiguous conduct consistent with regulatory compliance does not clear the bar [1]. Justice Ketanji Brown Jackson authored the opinion [1].
The case, Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., arose from Amarin's claim that Hikma's generic label for its cardiovascular drug induced physicians to prescribe the product for a patented indication that Hikma had carved out of its so-called skinny label [2]. A skinny label, authorized under the Hatch-Waxman Act, permits a generic manufacturer to launch without seeking approval for patented uses, listing only indications whose patents have expired or been licensed [2]. The Federal Circuit had allowed Amarin's inducement claim to proceed, reasoning that Hikma's broader market conduct, including certain promotional materials, could support an inference of intent to encourage the infringing use [1]. The Supreme Court disagreed and reversed [1].
The ruling resets the pleading standard for § 271(b) inducement claims across industries, not only pharmaceuticals [2]. Before this decision, brand manufacturers could point to a generic company's aggregate market conduct, sales figures suggesting substantial off-label use, or communications falling short of explicit encouragement, to survive a motion to dismiss [2]. The Court's holding demands something more targeted: allegations of specific, affirmative acts directed at the infringing use [1]. That standard forecloses inducement theories built primarily on circumstantial inferences from regulatory filings or general promotional activity [1].
The practical stakes extend well beyond the parties. The skinny-label pathway accounts for a significant share of generic drug launches, and branded manufacturers have increasingly weaponized inducement claims to delay or deter generic entry even after carve-outs [2]. By tightening the standard, the Court removes one of the more potent litigation tools available to block those launches [2]. IP litigators handling pending inducement matters, pharmaceutical or otherwise, will need to reassess whether existing complaint allegations satisfy the new specificity requirement before courts begin applying the decision on remand and in parallel district court proceedings [2].